In defense of β-blockers: a critical role in primary hypertension management.
No abstract available
References:
Shantsila E, Beevers DG, Lip GYH. For debate: the 2023 European Society of Hypertension guidelines - cause for concern. J Hypertens 2024; 42:948–950.
Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA) [published correction appears in J Hypertens. 2024;42:194]. J Hypertens 2023; 41:1874–2071.
Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338:b1665.
Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, et al. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336:1121–1123.
Manrique C, Giles TD, Ferdinand KC, Sowers JR. Realities of newer beta-blockers for the management of hypertension. J Clin Hypertens (Greenwich) 2009; 11:369–375.